Vitamin D as an anti-microbial and anti-inflammatory therapy for Cystic Fibrosis

Paediatr Respir Rev. 2014 Jun;15(2):154-62. doi: 10.1016/j.prrv.2013.11.002. Epub 2013 Nov 14.

Abstract

Cystic fibrosis (CF) is characterized by chronic infection and inflammation in the airways that lead to progressive lung damage and early death. Current anti-inflammatory therapies are limited by extensive adverse effects or insufficient efficacy. There is a large body of studies indicating beneficial anti-microbial and anti-inflammatory properties of vitamin D. Since most patients with CF present with vitamin D deficiency, and serum vitamin D levels demonstrate a positive correlation with lung function and negative correlation with airway inflammation and infection, correcting vitamin D deficiency may be an attractive therapeutic strategy in CF. The function of vitamin D is intricately tied to its metabolism, which may be impaired at multiple steps in patients with CF, with a potential to limit the efficacy of vitamin D supplementation. It is likely that the aforementioned beneficial properties of vitamin D require supplementation with doses of vitamin D markedly higher than those recommended to maintain proper bone function. This review will illustrate the potential for supplementation with vitamin D or its metabolites to modulate inflammation and improve defence against chronic infection in CF lung, as well as appropriate vitamin D supplementation strategies for improving lung function in CF.

Keywords: Anti-inflammatory; Anti-microbial; Cystic fibrosis; Treatment; Vitamin D.

Publication types

  • Review

MeSH terms

  • Bacterial Infections / drug therapy
  • Bacterial Infections / etiology
  • Child
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / microbiology
  • Humans
  • Inflammation / drug therapy
  • Inflammation / etiology
  • Vitamin D / therapeutic use*

Substances

  • Vitamin D